Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 4th Supervisory Board of Meikang Biotechnology Co., Ltd. It includes election of the Supervisory Board chairman and approval of continued use of idle raised funds for cash management. The document is short (1279 characters) and primarily serves as a meeting resolution announcement. It references compliance with regulatory requirements and mentions that detailed content is available on the designated disclosure website. There are no financial statements, detailed financial data, or comprehensive reports included. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement of board decisions and fund usage approvals, not a full report or financial statement.
2023-05-19 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificates, product names, registration numbers, validity periods, and intended uses. The document also discusses the potential impact on company performance and includes a risk warning. The document is short (950 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-19 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the 4th Board of Directors of Meikang Biotechnology Co., Ltd. It includes details about the meeting date, attendance, agenda items, voting results, and references to related documents. The content focuses on board decisions, specifically about the use of idle raised funds for cash management, and includes independent director opinions and regulatory compliance statements. There is no financial report, earnings data, or detailed management discussion. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions, not a full report or financial statement.
2023-05-19 Chinese
关于继续使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 美康生物科技股份有限公司 regarding the continued use of idle raised funds for cash management. It details the board and supervisory meetings approving the use of up to RMB 100 million of idle raised funds for low-risk financial products to increase returns without affecting the main investment projects. The document includes investment limits, risk controls, and opinions from independent directors and the sponsor institution. It is a regulatory announcement about the company's financing fund management and does not contain financial statements or detailed financial results. The document length is about 5,867 characters, which is sufficient for a full announcement but it is not a financial report like an annual or interim report. It is not a certification or a proxy statement. It is a formal disclosure related to capital management activities, specifically the use of raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-05-19 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring institution (中天国富证券有限公司) regarding the use of idle raised funds by 美康生物科技股份有限公司 for cash management. It includes specifics about the raised funds, usage, board and supervisory approvals, independent director opinions, and compliance with regulatory requirements. The document is not an announcement of a report but a substantive verification and opinion report on the use of raised funds, which aligns with regulatory requirements for monitoring and supervising the use of raised capital. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content fits best with an Audit Report / Information (AR) category, as it involves audit verification and regulatory compliance opinions related to the use of raised funds, which is typical for such filings in Chinese securities regulation contexts. Q2 2023
2023-05-19 Chinese
关于完成补选第四届监事会非职工代表监事及监事会主席的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the completion of a by-election for a non-employee representative supervisor and the election of the chairman of the supervisory board. It details personnel changes in the supervisory board, including resignation and election of members, and includes a brief resume of the newly elected chairman. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to reports or meetings beyond the supervisory board changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-05-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.